We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+18.28%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$648M
AUM Growth
-$71.9M
(-10%)
Cap. Flow
-$156M
Cap. Flow
% of AUM
-24%
Top 10 Holdings %
Top 10 Hldgs %
21.35%
Holding
491
New
67
Increased
62
Reduced
186
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ETF
ACWI
|
+$9.4M |
| 2 |
BELFB
Bel Fuse Inc Class B
BELFB
|
+$8.88M |
| 3 |
TriMas Corp
TRS
|
+$4.94M |
| 4 |
Cannae Holdings
CNNE
|
+$4.12M |
| 5 |
ExxonMobil
XOM
|
+$2.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maximus
MMS
|
+$8.25M |
| 2 |
DEN
Denbury Inc.
DEN
|
+$5.75M |
| 3 |
IBTD
iShares iBonds Dec 2023 Term Treasury ETF
IBTD
|
+$4.73M |
| 4 |
Valvoline
VVV
|
+$3.8M |
| 5 |
Northern Oil and Gas
NOG
|
+$3.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.66% |
| 2 | Consumer Discretionary | 18.68% |
| 3 | Industrials | 13.97% |
| 4 | Healthcare | 11.28% |
| 5 | Financials | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Kura Oncology
KURA
$921M
| $357K | 0.06% |
+24,804
| New | +$244K |
|
277
Harmonic Inc
HLIT
$1.18B
| $352K | 0.05% |
26,987
-2,494
| -8% | -$26.6K |
|
278
CRISPR Therapeutics
CRSP
$4.64B
| $348K | 0.05% |
+5,560
| New | +$307K |
|
|
WW
279
DELISTED
WW International
WW
| $341K | 0.05% |
38,996
-231,367
| -86% | -$1.96M |
|
280
D.R. Horton
DHI
$41.2B
| $336K | 0.05% |
+2,214
| New | +$273K |
|
281
Boyd Gaming
BYD
$6.59B
| $336K | 0.05% |
5,364
-8,573
| -62% | -$508K |
|
282
Eaton
ETN
$152B
| $333K | 0.05% |
1,381
-808
| -37% | -$178K |
|
283
DraftKings
DKNG
$12.1B
| $331K | 0.05% |
9,395
+726
| +8% | +$24.3K |
|
284
Builders FirstSource
BLDR
$7.79B
| $321K | 0.05% |
1,920
-451
| -19% | -$59.9K |
|
285
Spire
SR
$4.9B
| $318K | 0.05% |
5,105
-525
| -9% | -$31.3K |
|
|
P
286
Everpure Inc
P
$24.1B
| $316K | 0.05% |
8,870
-190
| -2% | -$6.66K |
|
287
Opendoor
OPEN
$3.69B
| $313K | 0.05% |
+72,264
| New | +$202K |
|
288
AES
AES
$10.6B
| $313K | 0.05% |
+16,275
| New | +$265K |
|
289
Scholar Rock
SRRK
$5.91B
| $312K | 0.05% |
+16,582
| New | +$206K |
|
290
Affirm
AFRM
$24.4B
| $312K | 0.05% |
+6,343
| New | +$183K |
|
291
Texas Roadhouse
TXRH
$13.2B
| $308K | 0.05% |
+2,519
| New | +$269K |
|
292
Darden Restaurants
DRI
$23.3B
| $301K | 0.05% |
1,829
-450
| -20% | -$68.1K |
|
293
Vitesse Energy
VTS
$637M
| $299K | 0.05% |
+13,658
| New | +$315K |
|
294
Diamondback Energy
FANG
$56.4B
| $296K | 0.05% |
1,906
-2,226
| -54% | -$349K |
|
295
ThredUp
TDUP
$759M
| $291K | 0.04% |
129,125
-310,330
| -71% | -$806K |
|
296
Consolidated Water Co
CWCO
$470M
| $286K | 0.04% |
+8,041
| New | +$265K |
|
297
GXO Logistics
GXO
$6.08B
| $285K | 0.04% |
4,658
-24,492
| -84% | -$1.37M |
|
298
ACM Research
ACMR
$5.33B
| $281K | 0.04% |
14,385
-7,300
| -34% | -$128K |
|
299
Barclays
BCS
$95.1B
| $268K | 0.04% |
34,003
-17,257
| -34% | -$124K |
|
300
Unilever
UL
$132B
| $267K | 0.04% |
4,899
-410
| -8% | -$22.1K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
RPAM
BBI
SSG
Advisory Research's Q4 2023 Portfolio in Review
As of Q4 2023, Advisory Research held 491 positions worth $648M, down 10% from $720M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Advisory Research withdrew a net $156M in Q4 2023, closing 160 positions and reducing 186 holdings. Its most notable exit was Denbury Inc., an estimated $5.75M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Advisory Research opened a new position in TriMas Corp worth $5.06M.
- Advisory Research's largest Q4 2023 buy was TriMas Corp: 199,840 shares worth $5.06M.
- Advisory Research added most to iShares MSCI ACWI ETF in Q4 2023, an estimated $9.4M increase.
- Advisory Research's biggest Q4 2023 reduction was Maximus, cutting an estimated $8.25M.
- Advisory Research fully exited Denbury Inc. in Q4 2023, selling an estimated $5.75M.
- Advisory Research's ten largest holdings make up 21% of its $648M portfolio in Q4 2023.
- Advisory Research opened 67 new positions and closed 160 in Q4 2023.
- Advisory Research's portfolio value fell 10% quarter-over-quarter to $648M.
Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.